Rapport Therapeutics
RAPP
30.86
-0.29
-0.93%
Rapport Therapeutics
US · RAPP
#2970 by market cap
Listed 2024
30.86
-0.29
-0.93%
Live - 5344 symbols - heartbeat 168s ago
· 2026-10-08 07:00
Pre-market
31.71
+2.75%
After-hours
30.86
0.00%
Overnight
30.86
0.00%
- Market cap
- 1.48B
- P/E (TTM)i
- -10.18
- P/Bi
- 3.50
- EPSi
- -2.86
- Div yieldi
- 0.00%
- 52W posi
- 24%
Reader sentiment
Are you bullish or bearish on RAPP?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
61.80 +100.3%
Price target rangecurrent 30.86
Low50.00
Avg61.80
High75.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | BTIG | -- | BUY | 75.00 |
| 2026-09-23 | William Blair | -- | BUY | -- |
| 2026-09-23 | Raymond James | -- | BUY | -- |
| 2026-09-23 | Truist Financial | -- | BUY | -- |
| 2026-09-23 | H.C. Wainwright | -- | BUY | 66.00 |
| 2026-09-22 | TD Cowen | -- | BUY | -- |
| 2026-09-22 | BTIG | -- | BUY | 75.00 |
| 2026-09-22 | Goldman Sachs | -- | BUY | 62.00 |
| 2026-09-18 | JonesTrading | -- | BUY | 50.00 |
| 2026-09-16 | JonesTrading | -- | BUY | 50.00 |
| 2026-09-16 | BTIG | -- | BUY | 75.00 |
| 2026-09-16 | Stifel | -- | BUY | 56.00 |
| 2026-09-15 | Truist Financial | -- | BUY | -- |
| 2026-09-02 | JonesTrading | -- | BUY | 50.00 |
| 2026-08-27 | BTIG | -- | BUY | 65.00 |
| 2026-08-19 | William Blair | -- | BUY | -- |
| 2026-08-19 | BTIG | -- | BUY | 65.00 |
| 2026-08-17 | Raymond James | -- | BUY | 75.00 |
| 2026-08-17 | H.C. Wainwright | -- | BUY | 66.00 |
| 2026-08-13 | Stifel | -- | BUY | 56.00 |
| 2026-08-13 | H.C. Wainwright | -- | BUY | 66.00 |
| 2026-08-12 | H.C. Wainwright | -- | BUY | 66.00 |
| 2026-08-06 | JonesTrading | -- | BUY | 50.00 |
| 2026-08-06 | Truist Financial | -- | BUY | 56.00 |
| 2026-08-05 | William Blair | -- | BUY | -- |
Quant vs Street three independent views, side by side
StockVane factor grade
B-
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 07:00:02 · For reference only, not investment advice and not tailored to your situation.